The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two ...

Rob Davis emphasized Merck's strong performance in 2024, driven by demand for KEYTRUDA, the launch of WINREVAIR, and robust growth in Animal Health. Davis highlighted challenges in GARDASIL sales in ...

In a report released on January 30, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research ...

Merck & Co Inc (MRK) reports robust sales growth driven by KEYTRUDA and WINREVAIR, while navigating GARDASIL demand issues in ...

Gossamer Bio Inc. has released new data showing its inhaled kinase inhibitor, seralutinib, has long-lasting effects on ...

Merck posted Q4 sales of $15.62 billion, driven by Keytruda's 19% growth. FY25 guidance lags estimates, citing Gardasil ...

Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.